14-day Premium Trial Subscription Sign Up For FreeGet Free

Bellicum Pharmaceuticals Stock Forecast NASDAQ:BLCM

$1.46 (4.29%)

Volume: 63k

Closed: Jan 19, 2022

Hollow Logo Score: -1.105

Bellicum Pharmaceuticals Stock Forecast

$1.46 (4.29%)

Volume: 63k

Closed: Jan 19, 2022

Score Hollow Logo -1.105

Bellicum Pharmaceuticals Company Profile

Life Science Plaza

Houston TX 77030



Industry: Biotechnology

Sector: Healthcare

Bellicum Pharmaceuticals


Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company’s preclinical product candidates include BPX-601, a chimeric antigen receptor (CAR-T) product candidate for treating solid tumors expressing the prostate stem cell antigen; BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma; and BPX-401, a CAR-T product candidate for the treatment of hematological cancers that express the CD19 antigen. The company has a research collaboration agreement with Holland's Leiden University Medical Center to discover and validate natural high-affinity T cell receptor product candidates targeting various cancers. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE